Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

[1]  Robin L. Jones,et al.  Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study , 2021, Nature Cancer.

[2]  S. Sangrajrang,et al.  CoronaVac induces lower neutralising activity against variants of concern than natural infection , 2021, The Lancet Infectious Diseases.

[3]  J. Klingström,et al.  Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination , 2021, The New England journal of medicine.

[4]  J. Münch,et al.  Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination , 2021, Nature Medicine.

[5]  R. Scheuermann,et al.  Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals , 2021, Cell Reports Medicine.

[6]  E. Wherry,et al.  Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. , 2021, medRxiv.

[7]  C. Rice,et al.  Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection , 2021, Nature.

[8]  K. Pradhan,et al.  Seroconversion rates following COVID-19 vaccination among patients with cancer , 2021, Cancer Cell.

[9]  E. Wherry,et al.  CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer , 2021, Nature Medicine.

[10]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[11]  L. Piemonti,et al.  Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival , 2021, Nature Communications.

[12]  A. Fiore-Gartland,et al.  Evidence for antibody as a protective correlate for COVID-19 vaccines , 2021, Vaccine.

[13]  J. Warner,et al.  Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium , 2021, Annals of Oncology.

[14]  C. Swanton,et al.  Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains , 2021, bioRxiv.

[15]  Evelien M. Adriaenssens,et al.  CoronaHiT: high-throughput sequencing of SARS-CoV-2 genomes , 2021, Genome medicine.

[16]  A. Harries,et al.  Faculty Opinions recommendation of Association of Smoking and Cumulative Pack-Year Exposure With COVID-19 Outcomes in the Cleveland Clinic COVID-19 Registry. , 2021, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[17]  D. Robertson,et al.  A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research , 2021, PLoS biology.

[18]  P. McKay,et al.  Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice , 2021, Nature Communications.

[19]  J. Zein,et al.  Association of Smoking and Cumulative Pack-Year Exposure With COVID-19 Outcomes in the Cleveland Clinic COVID-19 Registry. , 2021, JAMA internal medicine.

[20]  Gavin J. D. Smith,et al.  Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients , 2021, Cell Reports.

[21]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[22]  A. Coolen,et al.  Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients , 2021, Cancer Cell.

[23]  A. Achiron,et al.  Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies , 2021, Therapeutic advances in neurological disorders.

[24]  K. Pradhan,et al.  Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy , 2020, Nature Cancer.

[25]  N. Rosenthal,et al.  Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19 , 2020, JAMA network open.

[26]  Nguyen H. Tran,et al.  T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial , 2020, Nature Medicine.

[27]  M. Nussenzweig,et al.  Evolution of Antibody Immunity to SARS-CoV-2 , 2020, bioRxiv.

[28]  M. Malim,et al.  Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans , 2020, Nature Microbiology.

[29]  G. Curigliano,et al.  Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2 , 2020, Annals of Oncology.

[30]  A. Iafrate,et al.  COVID-19 neutralizing antibodies predict disease severity and survival , 2020, medRxiv.

[31]  A. Sette,et al.  Interferon-γ Release Assay for Accurate Detection of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Response , 2020, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[32]  P. Dormitzer,et al.  COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.

[33]  Lisa E. Gralinski,et al.  Animal models for COVID-19 , 2020, Nature.

[34]  J. Greenbaum,et al.  Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.

[35]  A. Swerdlow,et al.  Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study , 2020, Cell.

[36]  G. Curigliano,et al.  Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies , 2020, European Journal of Cancer.

[37]  V. Jiménez‐Yuste,et al.  Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study , 2020, Journal of Hematology & Oncology.

[38]  D. Kerr,et al.  COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study , 2020, The Lancet Oncology.

[39]  S. Mallal,et al.  Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans , 2020, Science.

[40]  Nichollas E. Scott,et al.  Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19 , 2020, Nature Medicine.

[41]  K. Bhaskaran,et al.  Factors associated with COVID-19-related death using OpenSAFELY , 2020, Nature.

[42]  Robin L. Jones,et al.  Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer , 2020, European Journal of Cancer.

[43]  Morten Nielsen,et al.  Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.

[44]  A. Sette,et al.  Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome , 2020, Science Immunology.

[45]  E. Robilotti,et al.  Determinants of COVID-19 disease severity in patients with cancer , 2020, Nature Medicine.

[46]  Robert L. Goldstone,et al.  Scalable and robust SARS-CoV-2 testing in an academic center , 2020, Nature Biotechnology.

[47]  Mike Clarke,et al.  A minimal common outcome measure set for COVID-19 clinical research , 2020, The Lancet Infectious Diseases.

[48]  V. Torri,et al.  COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study , 2020, The Lancet Oncology.

[49]  O. Schwartz,et al.  IgA dominates the early neutralizing antibody response to SARS-CoV-2 , 2020, Science Translational Medicine.

[50]  Loise M. Francisco,et al.  The PD-1 Pathway Regulates Development and Function of Memory CD8+ T Cells following Respiratory Viral Infection. , 2020, Cell reports.

[51]  Alokkumar Jha,et al.  Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study , 2020, The Lancet.

[52]  D. Kerr,et al.  COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study , 2020, The Lancet.

[53]  Linqi Zhang,et al.  Human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, Nature.

[54]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[55]  Philip A. Ewels,et al.  The nf-core framework for community-curated bioinformatics pipelines , 2020, Nature Biotechnology.

[56]  M. Okano,et al.  Cohort Study , 2020, Definitions.

[57]  J. Bridgewater,et al.  COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort study , 2020, Therapeutic advances in medical oncology.

[58]  S. Crotty.  T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. , 2019, Immunity.

[59]  Paolo Di Tommaso,et al.  Nextflow enables reproducible computational workflows , 2017, Nature Biotechnology.

[60]  Jincun Zhao,et al.  T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice , 2010, Journal of Virology.

[61]  A. Waisman,et al.  PD‐1 signalling in CD4+ T cells restrains their clonal expansion to an immunogenic stimulus, but is not critically required for peptide‐induced tolerance , 2010, Immunology.

[62]  V. Preedy,et al.  Prospective Cohort Study , 2010 .